Cardiovascular toxicities from systemic breast cancer therapy. - Wikidata - wikimedia - TriplyDB

Cardiovascular toxicities from systemic breast cancer therapy.

Cardiovascular toxicities from systemic breast cancer therapy.

http://www.wikidata.org/entity/Q34630349

about

Cancer drug related cardiotoxicity during breast cancer treatment.Cardiovascular toxicities of breast cancer treatment: emerging issues in cardio-oncology.Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study.Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients.Protective Mechanism of Hydrogen Sulfide against Chemotherapy-Induced Cardiotoxicity.The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells.

P2860

Q30251498-BDE60917-0D85-4518-A9BD-1DC3444471CF Q35189734-2F64FFA8-1047-4905-8C4D-37147CFA1148 Q37560059-748DA2E1-5ADD-4031-B347-93E5D4501470 Q39344380-E1901856-0DA7-49E4-8ADC-BBDD1F563566 Q41245359-2BE2777A-5549-45A7-8DA8-FBA2F172038A Q49706717-55AAA8A5-A0E7-40F5-890A-D0FE3DBA8478 Q55032232-D56503B9-CF8A-4CC5-9884-045675ADE115

P2860

Cardiovascular toxicities from systemic breast cancer therapy.

http://www.wikidata.org/entity/Q34630349

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Cardiovascular toxicities from systemic breast cancer therapy.

@ast

Cardiovascular toxicities from systemic breast cancer therapy.

@en

Cardiovascular toxicities from systemic breast cancer therapy.

@nl

type

label

Cardiovascular toxicities from systemic breast cancer therapy.

@ast

Cardiovascular toxicities from systemic breast cancer therapy.

@en

Cardiovascular toxicities from systemic breast cancer therapy.

@nl

prefLabel

Cardiovascular toxicities from systemic breast cancer therapy.

@ast

Cardiovascular toxicities from systemic breast cancer therapy.

@en

Cardiovascular toxicities from systemic breast cancer therapy.

@nl

P1433

Q34630349-5D849110-6D95-49E5-B1C0-AD2ECB676093

P1476

Q34630349-9C486D48-E367-4408-858C-4B56B2B6D98C

P2093

Q34630349-A26D677D-83F9-4527-9A9A-7EC5CE0F381F

Q34630349-CB760F9A-D3BF-4FEF-BC69-BB86C1E9B655

P2860

Q34630349-006F3243-096B-4EF7-B89C-A2C6C4910447

Q34630349-03A6A0FF-9C3E-4BA3-A720-A7A244EB2639

Q34630349-08875D04-8E92-4F8D-8472-91EAC9A42256

Q34630349-08AC3F78-508D-4BE1-AC85-6F79B7400CD5

Q34630349-095774CC-7A80-49AE-96A2-11134D3ECD21

Q34630349-0A6DB441-0264-4F85-8439-45B79BBD9CD2

Q34630349-0DB2C9B9-BEA7-458C-B2D1-077CFDFB3BC5

Q34630349-0EF8F578-BD13-4695-BD5F-380A0B94E387

Q34630349-0FB36126-25DC-47B1-9119-2CCA1C6227F1

Q34630349-11B4817B-BFCB-484B-B701-1A92EB84AE1E

P304

Q34630349-E89CB96D-0D12-4FAA-BBFA-F7D19A9F93B0

P31

Q34630349-885D3C21-ECA4-4372-9D41-CA9212E78B1D

P356

Q34630349-86FF9080-E95B-4DDF-8A1A-4B55A0E914A4

P478

Q34630349-03634D9A-04AD-4F9A-8CB4-EEFEF74EBF28

P577

Q34630349-897B7AAF-878C-4FFB-B3C3-F19FB0AC7112

P5875

Q34630349-B555AE43-2805-4B0E-8A03-5058259B2FF5

P698

Q34630349-249688FA-B909-452B-AB66-542F2CA4EC0A

P921

Q34630349-52D0164A-0742-404D-93D7-CBB382076A18

P932

Q34630349-241F7BBE-A60E-4212-BAAF-CDB11CF0A17C

P356

FONC.2014.00346

P1433

Frontiers in Oncology

P1476

Cardiovascular toxicities from systemic breast cancer therapy.

@en

P2093

Serena Wong

http://www.w3.org/2001/XMLSchema#string

Shuang Guo

http://www.w3.org/2001/XMLSchema#string

P2860

2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Trastuzumab containing regimens for early breast cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Cardiac dysfunction in the trastuzumab clinical trials experience

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer

Risk factors for doxorubicin-induced congestive heart failure

P304

346

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FONC.2014.00346

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2014-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270001363

http://www.w3.org/2001/XMLSchema#string

P698

25538891

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

4255485

http://www.w3.org/2001/XMLSchema#string